Bigelow Investment Advisors LLC trimmed its position in CME Group Inc (NASDAQ:CME) by 3.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,900 shares of the financial services provider’s stock after selling 104 shares during the quarter. Bigelow Investment Advisors LLC’s holdings in CME Group were worth $477,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. raised its position in shares of CME Group by 8.2% in the 4th quarter. BlackRock Inc. now owns 24,250,752 shares of the financial services provider’s stock worth $4,562,052,000 after acquiring an additional 1,828,640 shares in the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of CME Group by 18,502.9% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 16,220,459 shares of the financial services provider’s stock worth $86,000 after acquiring an additional 16,133,266 shares in the last quarter. FMR LLC raised its position in shares of CME Group by 114.7% in the 4th quarter. FMR LLC now owns 6,198,088 shares of the financial services provider’s stock worth $1,165,984,000 after acquiring an additional 3,310,989 shares in the last quarter. Geode Capital Management LLC increased its position in CME Group by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 4,715,269 shares of the financial services provider’s stock valued at $885,776,000 after buying an additional 537,917 shares in the last quarter. Finally, Northern Trust Corp increased its position in CME Group by 7.6% during the 4th quarter. Northern Trust Corp now owns 4,169,737 shares of the financial services provider’s stock valued at $784,411,000 after buying an additional 293,957 shares in the last quarter. Institutional investors and hedge funds own 84.83% of the company’s stock.
Shares of NASDAQ:CME opened at $178.01 on Friday. CME Group Inc has a 1 year low of $153.90 and a 1 year high of $197.08. The stock has a market cap of $63.69 billion, a P/E ratio of 26.10, a price-to-earnings-growth ratio of 3.57 and a beta of 0.29. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.15.
CME Group (NASDAQ:CME) last announced its quarterly earnings data on Thursday, February 14th. The financial services provider reported $1.77 earnings per share for the quarter, beating analysts’ consensus estimates of $1.75 by $0.02. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. CME Group had a return on equity of 9.85% and a net margin of 45.53%. The company’s revenue was up 37.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.12 earnings per share. Research analysts expect that CME Group Inc will post 6.81 EPS for the current fiscal year.
CME has been the topic of several recent analyst reports. JPMorgan Chase & Co. reduced their target price on CME Group from $164.00 to $150.00 and set an “underweight” rating on the stock in a research report on Friday, March 22nd. BidaskClub lowered CME Group from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. Deutsche Bank reduced their target price on CME Group from $220.00 to $214.00 and set a “buy” rating on the stock in a research report on Friday, March 15th. Bank of America reaffirmed a “neutral” rating and set a $191.00 target price (down from $200.00) on shares of CME Group in a research report on Friday, January 11th. They noted that the move was a valuation call. Finally, Rosenblatt Securities lowered CME Group from a “neutral” rating to a “sell” rating in a research report on Thursday, April 18th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $192.00.
In other news, CFO John W. Pietrowicz sold 2,500 shares of the stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $168.27, for a total value of $420,675.00. Following the transaction, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at $5,949,017.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey M. Bernacchi sold 10,087 shares of the stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $177.94, for a total value of $1,794,880.78. Following the completion of the transaction, the director now directly owns 42,004 shares in the company, valued at $7,474,191.76. The disclosure for this sale can be found here. Insiders sold 28,489 shares of company stock worth $4,948,996 over the last three months. Corporate insiders own 1.20% of the company’s stock.
WARNING: This news story was originally posted by Highlight Press and is owned by of Highlight Press. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://highlightpress.com/2019/04/26/bigelow-investment-advisors-llc-lowers-holdings-in-cme-group-inc-cme.html.
CME Group Profile
CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.
Featured Story: How is diluted EPS different from basic EPS?
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc (NASDAQ:CME).
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.